Spect Technologies Inc.
Spect Technologies Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Spect Technologies Inc..
Spect Technologies Inc. is a company.
Key people at Spect Technologies Inc..
Spect Technologies Inc. (Spect Inc.) is a digital health company founded in 2017 that develops an AI-enabled telemedicine platform for early detection of eye diseases, primarily using portable retinal imaging to prevent blindness and screen for systemic conditions like stroke, diabetes, heart attack, Alzheimer's, and Parkinson's.[1][2][3][5] Its core product, EyeLogic, includes a handheld retinal camera that allows medical assistants to capture images in clinics, hospitals, or patients' homes, with AI analysis and ophthalmologist reports delivered in minutes to hours, serving hospitals, health systems, and ambulatory practices.[3][4][5] The platform addresses care gaps in eye screening, targeting the 93 million U.S. adults at risk of vision loss by enabling fast, cost-effective exams without upfront costs via a subscription model, with deployments across eight U.S. states and $5.1M in total funding, including a $3.5M seed round in 2021.[4][5]
Spect Inc. was founded in 2017 in Salt Lake City, Utah (with early ties to Palo Alto, CA, and incubation at Altitude Labs), by co-founder and CEO Mike Ricci, who envisioned the eye as "the body’s check engine light" for detecting not just eye diseases but whole-body risks.[2][3][5] The idea emerged from addressing pain points in retinal screening, such as delays and high costs, leveraging data science and AI to build the world's largest retinal dataset.[1][5] Early traction came with a $3.5M Series Seed round in November 2021 from investors like Morado Ventures, AME Cloud Ventures, XTX Ventures, and 10x Group, funding platform expansion, AI enhancements, and team growth while deploying tech in over eight states.[1][4][5]
Spect rides the telemedicine and AI-driven preventive health wave, capitalizing on post-pandemic demand for accessible diagnostics amid a $19B nuclear medicine market (contextually adjacent via imaging trends) and 93M U.S. adults at vision loss risk.[4][5][6] Timing aligns with rising diabetes prevalence and regulatory emphasis on cost-effective screenings, enabling non-specialists to close care gaps in underserved areas.[1][5] Market forces like portable medtech adoption and AI data moats favor Spect, influencing the ecosystem by scaling retinal data for broader health analytics and partnering with health systems to normalize "check engine light" body scans.[1][3]
Spect is poised to expand its retinal dataset and AI for predictive whole-body health insights, potentially integrating with wearables or expanding globally beyond U.S. states.[1][5] Trends like AI personalization in diagnostics and value-based care will accelerate growth, especially with aging populations and chronic disease surges. Its influence may evolve toward platform leadership in multi-disease screening, blending eye health with systemic prevention to redefine accessible medtech. This positions Spect as a key player in data-driven blindness prevention, echoing its founding mission.[1][2]
Key people at Spect Technologies Inc..
